Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Monte Rosa Therapeutics, Inc. (GLUE)

10.66 +0.18 (+1.72%)
At close: October 27 at 4:00:01 PM EDT
10.90 +0.24 (+2.25%)
Pre-Market: 7:40:45 AM EDT
Trade GLUE on Coinbase
Chart Range Bar
Loading chart for GLUE
  • Previous Close 10.48
  • Open 10.60
  • Bid 7.61 x 200
  • Ask 13.47 x 200
  • Day's Range 10.34 - 10.71
  • 52 Week Range 9.68 - 25.77
  • Volume 1,457,929
  • Avg. Volume 1,405,739
  • Market Cap (intraday) 909.441M
  • Beta (5Y Monthly) 1.37
  • PE Ratio (TTM) --
  • EPS (TTM) -1.75
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 26.88
  • Zacks Rating Bullish

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

www.monterosatx.com

173

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GLUE
32.02%
S&P 500 (^GSPC)
12.81%

1-Year Return

GLUE
13.47%
S&P 500 (^GSPC)
12.33%

3-Year Return

GLUE
283.45%
S&P 500 (^GSPC)
87.56%

5-Year Return

GLUE
59.22%
S&P 500 (^GSPC)
69.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 8.97M
Earnings -43.4M
Profit Margin -483.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-40M
-20M
0
-1500.0%
-1000.0%
-500.0%

Analyst Insights

View More

Analyst Price Targets

19.00
26.88 Average
10.66 Current
37.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/5/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 25 -> 25

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    894.08M

  • Enterprise Value

    310.97M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    33.68

  • Price/Book (mrq)

    1.83

  • Enterprise Value/Revenue

    10.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -21.63%

  • Return on Equity (ttm)

    -42.66%

  • Revenue (ttm)

    28.73M

  • Net Income Avi to Common (ttm)

    -161.12M

  • Diluted EPS (ttm)

    -1.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    621.1M

  • Total Debt/Equity (mrq)

    7.80%

  • Levered Free Cash Flow (ttm)

    -74.45M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

10.66 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: